CSIMarket
 
Surrozen Inc   (SRZN)
Other Ticker:  
 
 
Price: $13.6500 $0.07 0.515%
Day's High: $13.8999 Week Perf: -4.21 %
Day's Low: $ 13.11 30 Day Perf: 15 %
Volume (M): 5 52 Wk High: $ 14.40
Volume (M$): $ 68 52 Wk Avg: $9.17
Open: $13.57 52 Wk Low: $0.52



 Market Capitalization (Millions $) 28
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -35
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 0

Surrozen Inc
Surrozen Inc. is a biotechnology company headquartered in San Francisco, California. It was founded in 2016 and is focused on developing novel therapeutics to regenerate damaged tissues and organs. Surrozen utilizes its proprietary technology platform to discover and develop drugs that target the Wnt signaling pathway, which plays a critical role in tissue repair and regeneration.

The company's therapeutics aim to activate the body's natural regenerative processes by stimulating specific cell types to enhance tissue healing. Surrozen's innovative approach holds potential for treating a wide range of diseases and injuries, including those affecting the liver, lung, and gastrointestinal system.

Surrozen has garnered significant attention and investment from prominent pharmaceutical companies and venture capital firms due to the promising potential of its technology. By leveraging advancements in stem cell biology and regenerative medicine, Surrozen seeks to revolutionize the treatment of various debilitating conditions and improve patient outcomes.

While still in the early stages of development, Surrozen has a strong team of scientists and industry experts dedicated to advancing its pipeline of regenerative therapeutics. The company's ultimate goal is to translate cutting-edge research into transformative therapies that have a profound impact on patients suffering from chronic or acute tissue damage.


   Company Address: 171 Oyster Point Blvd South San Francisco 94080 CA
   Company Phone Number: 489-9000   Stock Exchange / Ticker: NASDAQ SRZN
   SRZN is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Surrozen's Strategic Shift towards SZN-043 for Alcohol-Associated Hepatitis Signals Promising Research Focus

Published Thu, Jan 18 2024 1:30 PM UTC

In a recent corporate update, biopharmaceutical company Surrozen announced a strategic prioritization of its clinical programs to concentrate on the development of SZN-043, a potential treatment for Alcohol-Associated Hepatitis (AAH). This decision marks a significant shift in Surrozen's research focus and holds considerable promise for addressing a pressing unmet medical ne...

Surrozen Inc

Surrozen Inc Surpasses Expectations: Posts Promising Q3 2023 Earnings with Operating Deficit at $-11.189 Million

Surrozen Inc., a biotechnology and pharmaceutical company, recently released its third-quarter financial results for 2023 which revealed an operating deficit of $-11.189 million. While the company has not generated any revenue during this period, the improvement from the operating deficit of $-13.605 million in the third quarter of 2022 has shown promise for Surrozen Inc. This improvement has provided market observers with optimism regarding the company's performance.
During the third quarter of 2023, Surrozen Inc.'s management demonstrated a more cost-effective approach, successfully reducing the operating deficit to $-10.445 million. This accomplishment has further bolstered confidence in the company's ability to navigate the market and improve its financial standing. The management's efforts have been applauded for their impact in making Surrozen Inc. a more efficient and profitable entity.

Surrozen Inc

Surrozen Inc Emerges from Losses with Impressive Market and Stock Performance, Gaining 6.12% in 5 Trading Days and 51.34% YTD

Surrozen Inc: An Overview of Market and Stock Performance
Surrozen Inc, a biotechnology company focused on developing regenerative medicine therapies, has recently been in the spotlight due to its impressive market and stock performance. Over the past five trading days, the company's shares have recorded a solid gain of 6.12%. This upward trend is also evident when we take a look at the year-to-date performance, with Surrozen Inc shares showing an impressive increase of 51.34% in 2023.
However, it is essential to provide some context regarding the stock's position in the market. Currently trading on the NASDAQ, Surrozen Inc shares are currently -31.3% below its 52-week average. This means that while the recent performance has been positive, the stock is still recovering from previous losses and has not reached its highest trading levels in the past year.

Surrozen Inc

Surrozen Inc's Business Expenses Skyrocket in Recent Fiscal Period as Operating Deficit Doubles

Surrozen Inc, a lesser known business in the Biotechnology & Pharmaceuticals industry, recently announced an operating deficit of $-14.592 million for the first quarter of 2023. However, this is not a surprising occurrence for companies in the emerging stage of development, and investors are hopeful for additional revenue sources to come soon.
The current deficit is larger than the deficit encountered during the same period last year, increasing from $-7.947 million to $-14.297 million. This may raise concerns among investors, but it is important to note that companies in the early stages of development often have high operating costs and low revenue streams.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com